Qiagen, 5135-1220, digene HC2 CT-ID DNA Test

For 88 cervical samples (96 tests): CT Probe, Quality Controls, Calibrators, Capture Microplate, Reagents and Buffers

Features

- High clinical sensitivity and specificity
- Signal-amplified nucleic acid test with immunoassay simplicity
- Detects both symptomatic and asymptomatic CT infections

Product Details

The digene HC2CT-ID DNA Test is an in vitro microplate assay based on signal-amplified nucleic acid hybridization that uses chemiluminescence for the qualitative detection of Chlamydia trachomatis (CT) DNA from cervical specimens.

Performance

Method: Sensitivity
Brush: 97.7%
Swab: 92.3%

The digene HC2 CT-ID DNA Test provides high clinical sensitivity and specificity (see table).

Principle

The digene HC2 CT-ID DNA Test is a nucleic acid hybridization assay with signal amplification that utilizes microplate chemiluminescent detection. Specimens containing the target DNA hybridize with a specific CT RNA probe cocktail. The resultant RNA–DNA hybrids are captured onto the surface of a microplate well that is coated with antibodies specific for RNA–DNA hybrids. Immobilized hybrids are then reacted with alkaline phosphatase-conjugated antibodies specific for RNA–DNA hybrids, and detected with a chemiluminescent substrate. Several alkaline phosphatase molecules are conjugated to each antibody. Multiple conjugated antibodies bind to each captured hybrid, resulting in substantial signal amplification. As the substrate is cleaved by the bound alkaline phosphatase, light is emitted, which is measured as relative light units (RLUs) on a luminometer. The intensity of the light emitted denotes the presence or absence of target DNA in the specimen.

Procedure

Cervical specimens are collected and transported using the digene HC2 DNA Collection Device or digene Female Swab Specimen Collection Kit. Specimens are denatured using a denaturation reagent and heat. The probe mix is added, and hybridization is carried out in a hybridization microplate. Hybridized samples are transferred to a capture microplate for hybrid capture. A detection reagent is added, and a wash step is carried out. A second detection reagent is added, and detection is carried out on a luminometer.

After denaturation, the procedure can be fully automated on the Rapid Capture System through to sample detection. Detection is then carried out manually on a luminometer.

Reimbursement

The digene HC2 CT-ID DNA Test is recognized by the American Medical Association (AMA) and reimbursed using "amplified probe technique" CPT codes (when appropriate).

Applications

The digene HC2 CT-ID DNA Test is for qualitative detection of Chlamydia trachomatis (CT) in cervical specimens. The test can be used as a standalone test or as a follow-up test for detection of CT in specimens that were initially positive using the digene HC2 CT/GC DNA Test. The digene HC2 CT-ID DNA Test is indicated for use to identify symptomatic or asymptomatic women with Chlamydia trachomatis (CT) infection.